Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers

Next Previous
X
Search
Trial Profile

Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics; Immunotherapies; Protein tyrosine kinase inhibitors
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Jan 2021 Status changed from active, no longer recruiting to discontinued.
    • 12 Oct 2020 Planned End Date changed from 1 Feb 2021 to 1 Jan 2021.
    • 12 Oct 2020 Status changed from discontinued to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top